Teva's Biosimilar Boom Just Beginnings: Is It Time to Buy?
Teva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
Monthly budget adjustments keep your finances on track. Learn how small tweaks help you respond to income changes and shifting priorities.
27,140 articlesTeva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
A Perdoceo director recently exercised 9,308 options and sold shares, triggering questions for investors. This guide ...
A large open-market sale by Indivior's Chief Scientific Officer sparked questions about future risk and long-term val...
A sharp 20% drop has traders buzzing about Silicon Motion Technology. This guide breaks down the opportunity, the ris...
This week, plug power stock rocketed about 20% as earnings and feasibility signals fed optimism about hydrogen adopti...
Investors are scanning cannabis names for growth and resilience. Here are three clear reasons why Green Thumb Industr...
Before leading Goldman Sachs, David Solomon held a string of early jobs and learned a hard time-management lesson fro...
A court ruling over a $175 billion tariff scheme puts refunds on hold, widening the gap between import costs and cons...
July 16 could be a pivotal date for Nvidia and the broader AI chip ecosystem. This guide explains why Nvidia investor...
Howard Schultz and his wife plan a move to Florida as Washington considers a roughly 10% annual tax on earnings above...
Bilt rolls out an AI-driven Neighborhood Concierge to challenge Amazon in the home-commerce space, promising seamless...
Celina, Texas leads the nation in growth for a second year, marking a trend toward Texas suburbs where the american d...